Sanofi SA (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 200   

Articles published

SNY 53.19 +0.92 (1.76%)
price chart
Sanofi SA Rating Increased to Outperform at Mainfirst (SNY)
Sanofi SA (ADR) logo Mainfirst upgraded shares of Sanofi SA (NYSE:SNY) to an outperform rating in a research report sent to investors on Monday morning.
Sanofi SA Upgraded to "Outperform" by Mainfirst (SNY)  Watch List News (press release)
Related articles »  
Sanofi SA Upgraded to Outperform by Mainfirst (SNY)
Sanofi SA (ADR) logo Sanofi SA (NYSE:SNY) was upgraded by analysts at Mainfirst to an �outperform� rating in a research report issued to clients and investors on Monday.
Drug Stocks: Impax Laboratories Inc (NASDAQ:IPXL), Retrophin Inc (NASDAQ ...
On 20 JUNE Sanofi SA (ADR) (NYSE:SNY) reported $0.81 earnings per share for the quarter, missing the analysts' consensus estimate of $0.84 by $0.03.
Stocks in Considerable Figures- Penn West Petroleum (NYSE:PWE), Sanofi ...
Sanofi SA (ADR) (NYSE:SNY) [Trend Analysis] reported that nine new Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint of a greater percent reduction from baseline in low-density lipoprotein ...
Related articles »  
Versatile News at Street: Pearson (NYSE:PSO), Vodafone (NASDAQ:VOD ...
In last trading session, shares of Sanofi SA (ADR) (NYSE:SNY) fell -2.04%, closing the day at $50.97, after wavering among $50.83 and $51.73 during the trading session.
Related articles »  
Notable Stocks: Merck (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Novartis ...
Sanofi SA (ADR) (NYSE:SNY) increased its stake in the biopharmaceutical company and now holds about 22.5 percent of its outstanding shares.
Related articles »  
Volatility Measure: Ladenburg Thalmann (NYSEMKT:LTS), Sanofi (NYSE:SNY ...
Sanofi-Aventis confirms FDA recognizes Sanofi SA's (ADR) (NYSE:SNY) [Trend Analysis] New Drug Application for Toujeo.
Related articles »  
Roche's Asthma Treatment Succeeds In Mid-Phase Studies
But another drug being developed in a joint effort by Sanofi SA (ADR) (SNY) and Regeneron Pharmaceuticals Inc (REGN) is said to be a better option, by an analyst at Kepler Cheuvreux.
Related articles »  
Stocks in Good Figures- Chevron (NYSE:CVX), Rent-A-Center (NASDAQ:RCII ...
French drug maker Sanofi SA's (ADR)(NYSE:SNY) [Trend Analysis] Sanofi Pasteur division Friday declared that the publication in The Lancet of the detailed results of its first landmark phase III dengue vaccine efficacy study conducted in five countries ...
Related articles »  
Buzz Stocks: Zynga Inc, International Business Machines Corp., United ...
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA (ADR) (NYSE:SNY) announced their experimental atopic dermatitis treatment, dupilumab, significantly reduced itching and skin lesions on patients during a mid-stage trial.
Related articles »